NASDAQ OMX (NASDAQ: NDAQ) announces that the trading in Diamyd Medical AB (short name: DMYD B) shares commenced today on First North at NASDAQ OMX Stockholm. Diamyd Medical belongs to the Healthcare sector and is the eighth new company to be admitted to trading on First North in 2013.
Diamyd Medical is a diabetes company headquartered in Stockholm, Sweden. The company develops the diabetes vaccine Diamyd® and the active ingredient GAD for the treatment and prevention of type 1-diabetes. Two researcher-initiated Phase II studies with Diamyd® are ongoing. Diamyd Medical AB (formerly Diamyd Therapeutics AB) was recently spun out from the publicly traded Mertiva AB (formerly Diamyd Medical AB).
“The new company structure is well positioned to continue the work to find a cure for type 1-diabetes,” says Peter Zerhouni, CEO of Diamyd Medical. “As a separately listed entity on First North, Diamyd Medical is able to gain a stronger focus on the continued development of our diabetes vaccine while reaching out to a broad investor audience. We will also leverage our expertise and worldwide network in diabetes to assess the potential to expand our business in terms of products in the diabetes area.”
“We welcome Diamyd Medical to First North, one of Europe’s most liquid growth markets,” says Adam Kostyal, Senior Vice President at NASDAQ OMX. “We’ve experienced a marked inflow of life science companies and Diamyd is our fourth addition to the healthcare sector this year."
Diamyd Medical has appointed Remium Nordic AB as Certified Adviser.